



Molecular docking, synthesis, and *in vitro* activity testing of chalcone derivatives from *Boesenbergia rotunda* (L.) Mansf. against MCF-7 breast cancer cells

[Acoplamiento molecular, síntesis y actividad *in vitro* de derivados de chalcona de *Boesenbergia rotunda* (L.) Mansf. contra células MCF-7 de cáncer de mama]

Marsha A. Amelia¹, Dini Kesuma^{2*}, Aguslina Kirtishanti³, I Gede A. Sumartha², Maria Claudya¹

¹Master's Program of Industrial Pharmacy, University of Surabaya, Surabaya, Indonesia.

²Department of Pharmaceutical Chemistry, University of Surabaya, Surabaya, Indonesia.

³Department of Clinical and Community Pharmacy, University of Surabaya, Surabaya, Indonesia.

*E-mail: dinikesuma1302@gmail.com, dini_kesuma@staff.ubaya.ac.id

Abstract

Context: The chalcone derivative compounds (bis-2-chlorobenzoyloxichalcone and bis-3-chlorobenzoyloxichalcone) synthesized from pinostrobin, which is found in *Boesenbergia rotunda* (L.) Mansf., which has cytotoxic activity relative to the estrogen receptor alpha.

Aims: To determine the anticancer activity of chalcone derivative compounds synthesized from *B. rotunda* as an *in silico* and *in vitro* breast cancer candidate.

Methods: An *in silico* test was performed to predict the cytotoxic activity using AutoDockVina and the synthesis of chalcone and derivatives from pinostrobin compounds contained in *B. rotunda* using the green synthesis method through Williamson etherification reaction and phase-transfer catalyst (PTC)-assisted microwave irradiation. This activity was also tested *in vitro* using the microculture tetrazolium technique (MTT) assay of breast cancer cells (MCF-7) and normal cells (Vero cells).

Results: *In silico* tests predicted that chalcone derivatives were more cytotoxic at estrogen receptor alpha than lead compounds (pinostrobin and chalcone compound). *In vitro* tests showed that the bis-2-chlorobenzoyloxichalcone compound showed an IC₅₀ greater than 100 µg/mL, which indicated it was not active, and the bis-3-chlorobenzoyloxichalcone compound exhibited an IC₅₀ less than 100 µg/mL, which indicated it was moderately active. Thus, *in vitro* tests showed that two compounds were less potent against MCF-7 cells than the reference compound (tamoxifen). However, it was selective against MCF-7 breast cancer cells while not harming Vero cells.

Conclusions: The bis-2-chlorobenzoyloxichalcone and bis-3-chlorobenzoyloxichalcone compounds identified in *B. rotunda* exhibited a favorable selectivity index, suggesting moderate potential as anticancer candidates for breast cancer. However, further research and development are required to validate their efficacy and safety.

Keywords: breast cancer; chalcone; cytotoxic activity; estrogen receptor alpha; green synthesis.

Resumen

Contexto: Los compuestos derivados de chalcona (bis-2-clorobenciloxichalcona y bis-3-clorobenciloxichalcona) sintetizados a partir de pinostrobin, presente en *Boesenbergia rotunda* (L.) Mansf., muestran actividad citotóxica en relación con el receptor de estrógeno alfa.

Objetivos: Determinar la actividad anticancerígena de compuestos derivados de chalcona sintetizados a partir de *B. rotunda* como candidato para el cáncer de mama *in silico* e *in vitro*.

Métodos: Se realizó una prueba *in silico* para predecir la actividad citotóxica utilizando AutoDockVina y la síntesis de chalcona y derivados de compuestos de pinostrobin presentes en *B. rotunda* mediante el método de síntesis verde mediante la reacción de eterificación de Williamson e irradiación de microondas asistida por catalizador de transferencia de fase (PTC). Esta actividad también se evaluó *in vitro* mediante ensayo de microcultivo con tetrazolio (MTT) en células de cáncer de mama (MCF-7) y células normales (células Vero).

Resultados: Las pruebas *in silico* predijeron que los derivados de chalcona fueron más citotóxicos para el receptor de estrógeno alfa que los compuestos principales (pinostrobin y chalcona). Las pruebas *in vitro* mostraron que el compuesto bis-2-clorobenciloxichalcona presentó una CI₅₀ superior a 100 µg/mL, lo que indicó su inactividad, y el compuesto bis-3-clorobenciloxichalcona exhibió una CI₅₀ inferior a 100 µg/mL, lo que indicó su actividad moderada. Por lo tanto, las pruebas *in vitro* mostraron que dos compuestos fueron menos potentes contra las células MCF-7 que el compuesto de referencia (tamoxifeno). Sin embargo, fue selectivo contra las células de cáncer de mama MCF-7, sin dañar las células Vero.

Conclusiones: Los compuestos bis-2-clorobenciloxichalcona y bis-3-clorobenciloxichalcona identificados en *B. rotunda* exhibieron un índice de selectividad favorable, lo que sugiere un potencial moderado como candidatos anticancerígenos para el cáncer de mama. Sin embargo, se requiere mayor investigación y desarrollo para validar su eficacia y seguridad.

Palabras Clave: actividad citotóxica; cáncer de mama; chalcone; receptor de estrógeno alfa; síntesis verde.

ARTICLE INFO

Received: September 28, 2024.

Accepted: March 24, 2025.

Available Online: May 7, 2025.

AUTHOR INFO

ORCID:

[0000-0002-6612-372X](https://orcid.org/0000-0002-6612-372X) (DK)

[0000-0002-1690-2733](https://orcid.org/0000-0002-1690-2733) (AK)

[0000-0002-6950-3795](https://orcid.org/0000-0002-6950-3795) (IGAS)

INTRODUCTION

In recent decades, cancer has been a deadly disease that is of great concern in the field of research and therapeutic development, both in Indonesia and around the world. The Global Burden of Cancer (2021) data estimate the incidence and mortality rate of cancer worldwide at 19.3 million new cases. In the case of breast cancer, it is estimated that there are 2.3 million new cases (11.7%) (Sung et al., 2021). According to (The Global Cancer Observatory, 2021), Indonesia reports 396,914 new cancer cases, with breast cancer ranking first at 65,858 (16.6%), and a reported death rate of 22,430 (9.6%) from breast cancer.

Currently, several cancer therapies, including chemotherapy, radiotherapy, and immunotherapy, have demonstrated benefits for cancer patients. However, these therapies often come with side effects or multidrug resistance (MDR) mechanisms, which remain the primary cause of clinical treatment failure. These mechanisms can lead to reduced efficacy of chemotherapy drugs (Kesuma et al., 2022; Pratama et al., 2022), gradually diminishing their effectiveness, and causing cancer cells to develop resistance to anticancer drugs (Goldman, 2003; Kar, 2007; Tartarone et al., 2013). In the case of tamoxifen administration to patients with breast cancer, resistance developed after 3–5 years of use. Moreover, tamoxifen functions as an agonist in the endometrium, leading to the development of endometrial cancer over time. There are 30% of breast cancer patients in the early stages who develop endometrial cancer after Tamoxifen administration at a certain time (Ali et al., 2016).

ER- α is considered to be a receptor that is primarily involved in breast cancer development, making it an important target in breast cancer therapy. One adherent cell line that expresses estrogen receptor alpha (ER- α) is MCF-7 breast cancer cells (Ogba et al., 2014). However, MCF-7 cells develop resistance to selective estrogen receptor modulator (SERM) chemotherapeutic agents, namely tamoxifen (TAM). Breast cancer patients with estrogen receptor-positive (ER+) status primarily receive TAM (Clusan et al., 2023; Moerkens et al., 2014).

Therefore, a systematic elaboration process is necessary to further develop existing drugs, with the aim of obtaining new cancer drugs. According to Sun et al. (2023), this process involves using natural materials that can act as chemotherapeutic agents, making cancer cells more sensitive so that chemotherapeutic agents work better, and lessening the side effects of chemotherapeutic agents.

Fingerroot (*Boesenbergia rotunda* (L.) Mansf., family *Zingiberaceae*), also known as temu kunci in Indonesia, has the ability to increase the number of lymphocytes and specific antibodies, as well as kill cancer cells. Flavanones, flavones, and chalcones are the main flavonoids found in temu kunci extract (Atun and Handayani, 2017). Chalcone compounds play a significant role in the synthesis of various heterocyclic compounds, including flavones, isoxazoles, benzodiazepines, pyrazolines and their derivatives, and flavonols. This leads to the widespread use of chalcone analog compounds and their derivatives as target molecules in the search for active compounds, particularly as potential anticancer drugs (Dona et al., 2019). Strong biological activity has shown chalcone's potential as a chemotherapeutic agent, but its limited availability in nature compared to other flavonoid compounds necessitates an effective synthesis method (Villa et al., 2024). The process of creating chalcone compounds involves isolating pinostrobin from *B. rotunda*. The next step involves structurally modifying the lead compound to produce compounds that exhibit the desired activity. Therefore, structural modifications are anticipated to enhance selectivity, improve pharmacological activity, and minimize toxicity (Siswandono, 2016).

Therefore, in an effort to conserve the environment and utilize biodiversity, we must develop the latest cancer treatment methods based on natural resources. One such method involves synthesizing chalcone derivative compounds from the isolated *B. rotunda*. We used estrogen-a receptors with the PDB ID 6CHZ to do *in silico* tests on chalcone compounds and their derivatives for this study. The next stage is the isolation of compounds from the *B. rotunda*, the synthesis of chalcone and its derivatives from pinostrobin compounds isolated from the *B. rotunda* using the green synthesis method through the Williamson ether reaction and using microwave irradiation with the help of a phase-transfer catalyst (PTC). Purity and structure were tested using an IR spectrometer and a $^1\text{H-NMR}$ spectrometer. We further tested its cytotoxic activity *in vitro* using the MTT assay on MCF-7 cancer cells and Vero normal cells. This research aims to obtain and develop breast cancer chemotherapy drug candidates.

MATERIAL AND METHODS

Materials

Materials for molecular docking: marker compounds from *B. rotunda*, specifically pinostrobin and its derivatives (chalcones and chalcone derivatives),

which were made structural drawings using the MarvinSketch application, and estrogen-receptor with PDB ID 6CHZ, as well as the tamoxifen reference compound downloaded from the protein data bank (PDB).

Materials for physicochemical isolation, synthesis and analysis: *B. rotunda* powder (*B. rotunda*) (determined by UPT Laboratorium Herbal Materia Medica Batu, Indonesia), N-hexane p.a. (E.Merck, Germany), ethyl acetate p.a. (E.Merck, Germany), methanol, pinostrobin (compound isolated from *B. rotunda* powder), chalcone (2,6-dihydroxy-4-metoxychalcone) (compound synthesized from pinostrobin), 2-chlorobenzyl chloride (TCI, America), 3-chlorobenzyl chloride (TCI, America); NaOH p.a (E.Merck, Germany), tetrabutylammonium chloride p.a (E.Merck, Germany), chloroform (E.Merck, Germany), and MgSO₄ anhydrous (University of Surabaya, Indonesia).

Materials for *in vitro* test: Bis-2-chlorobenzyl-oxychalcone and bis-3- chlorobenzyl-oxychalcone synthesized compounds; tamoxifen (Indonesian FDA Laboratory Services (INFALABS, BPOM Indonesia); MCF-7 cell culture and Vero cells; DMEM culture medium; MI99 culture medium; fetal bovine serum (FBS); phosphate buffer saline (PBS); dimethylsulfoxide (DMSO); trypsin; penicillin-streptomycin, fungizone; 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) 0.5 mg/mL, SDS 10% in HCl 0.1 N.

Tools and equipment

Tools used for *in silico* tests: Computer hardware with CPU specifications Intel(R) Core (TM) i7-9700F CPU @ 3.00GHz, 16384MB RAM equipped with Windows 10 Education 64-bit operating system (Dell, Dell Technologies Inc., China), AutoDock Vina (The Scripps Research Institute, USA) and AutoDockTools 1.5.6 programs (The Scripps Research Institute, USA), PyRx program (PyRx LTD., UK), MarvinSketch program (ChemAxon, Hungary), Lipinski Rule of Five website (URL), and BIOVIA Discovery Studio Visualizer (BIOVIA Foundation, USA).

Tools used for isolation, synthesis, and structure confirmation were rotary evaporator (Buchi, Swiss); water bath (Memmert GmbH, Germany); Corning Hot Plate P351 (Thermo Fisher Scientific Inc., USA); Fisher-John Electrothermal Mel-Temp (Biobase Biotechnology, China); IR Spectrophotometer (Agilent, Agilent Technologies, USA) and ¹H-NMR Spectrometer 400 MHz (Agilent, Agilent Technologies, USA).

Tools used for *in vitro* tests were CO₂ incubator (Thermo Fisher Scientific Inc., USA); laminar air flow (Gelman Sciences); test tubes (Agilent Technologies, USA); vortex (Thermo Fisher Scientific Inc., USA); 96

well microplate (Falcon, Corning, China); inverted microscope (Zeiss 451235, Zeiss Axiovert, Zeiss, USA); haemocytometer (Thermo Scientific, Thermo Fisher Scientific Inc., USA); cell counter (Thermo Scientific, Thermo Fisher Scientific Inc., USA); ELISA-reader (Bio-Rad, Agilent, Agilent Technologies, USA).

Docking method validation

When performing docking protocols on chalcone derivative compounds using the Autodock 4.2.6 and Autogrid (AutoDock, The Scripps Research Institute, USA) programs, it is necessary to validate the method by redocking the native ligand (tamoxifen) to the protein whose native ligand has been removed. The parameter for validation of this method is the root mean square deviation (RMSD) value, with a tolerable value of ≤3.0 (Ramírez and Caballero, 2018).

In silico prediction of cytotoxic activity

Autodock software (Version 4.2.6) was used to predict the cytotoxic activity of these compounds. Molecular tethering simulations were performed between the test compound and estrogen receptor alpha PDB ID 6CHZ, containing the tamoxifen ligand, which was downloaded from the protein data bank (PDB) server.

To prepare the protein and ligand molecules, Mgl tools (version 1.5.6) were used, and to get a perfect/good grid parameter assignment of each ligand, the grid box was created by trial and error. Grid box centres X: -30.000, Y: -3.957, Z: -22.374 were used for docking calculation (Amelia et al., 2024). Subsequently, the docking process was performed by running the Lamarckian Genetic Algorithm. Here, default parameters and one hundred independent docking runs were performed for each chemical structure. Structure modification to obtain derivative compounds was performed using the Topliss approach method. The structure modification was carried out with the aim of obtaining new drugs that are more effective and reducing the side effects that have been known before.

Plant material

The *B. rotunda* rhizome (GPS coordinates: -7.867687882049943, 112.51928107745778) used in this study has been identified by the UPT Laboratorium Herbal Materia Medica Batu, Indonesia, with identification number 000.9.3/516/102.20/2024. The botanical classification of this plant is as follows:

Kingdom: *Plantae*

Division: *Magnoliophyta*

Class: *Monocotyledonae*

Order: *Zingiberales*

Family: *Zingiberaceae*

Genus: *Boesenbergia*

Species: *Boesenbergia rotunda* (L.) Mansf.

Synonym: *Boesenbergia pandurata* (Roxb.) Schlecht. = *Kaempferia pandurata* Roxb.

The reference for this determination was derived from the textbook (Backer and Bakhuizen Van Den Brink, 1968; Van Steenis, 2008), which served as the authoritative source for the plant's taxonomic classification.

Isolation of pinostrobin from *B. rotunda*

The determined *B. rotunda* powder was weighed as much as 2 kg of fine powder, then extracted using 20 L of n-hexane solvent by maceration and then remacerated three times. The remaining solvent was evaporated at 40°C under low pressure until the volume reached 1/3 of the initial volume using a rotary evaporator and evaporated in a fume hood. Then recrystallization was carried out by dissolving the crude crystals with hot methanol solvent and cooled in a refrigerator for 24 hours until crystals formed. The crystals formed were washed with hot methanol four times and allowed to stand at room temperature. Chemical structure identification was carried out using an IR spectrophotometer and a ¹H-NMR spectrophotometer at 400 MHz.

Synthesis of bis-2-chlorobenzoyloxychalcone and bis-3-chlorobenzoyloxychalcone


A 12.5 N NaOH solution was made in a beaker. The manufacturing step can be done by weighing 50 grams of NaOH (1.250 mmol). After that, add 100 mL of distilled water solution and stir until homogene-

ous. Pipette 2 mL of the finished 12.5 N NaOH solution using a syringe, then put it in a round-bottom flask. After that, add 0.2 g (0.74 mmol) of chalcone and 0.28 mL (2.22 mmol) of 2-chlorobenzyl chloride and 3-chlorobenzyl chloride, respectively, to each round-bottom flask. Add 0.01 g (0.025 mmol) tetrabutylammonium chloride. Heat the mixture in a microwave for 10 minutes at 200 watts. The purity test was characterized by thin layer chromatography (TLC) and melting point, while the structure identification of active bis-2-chlorobenzoyloxychalcone and bis-3-chlorobenzoyloxychalcone compounds utilized the following instruments: IR spectrophotometer and ¹H-NMR (McMurry, 2011; Pavia et al., 2009).

The reaction between chalcone from a synthesis of pinostrobin with 2-chlorobenzyl chloride and 3-chlorobenzyl chloride can be seen in Fig. 1.

In vitro test and selectivity index

The cell culture was incubated in DMEM and M199 media for 24 h in a 96-well plate (Kesuma et al., 2025). Cells were withdrawn individually using a micropipette, and then a sample solution consisting of synthesized compounds (chalcone derivatives) and the reference drug tamoxifen was added. The plate was incubated in a CO₂ incubator at 37°C for 24 hours. After incubation, the microplate was removed from the incubator, and the treatment media was discarded. Then, 100 µL of MTT solution was added to each well, including the cell control and media control wells. The plate was incubated in a CO₂ incubator at 37°C for 2 to 4 h and regularly observed under an inverted microscope to check for formazan formation. Once formazan formation was observed, the MTT reaction was stopped by adding 10% DMSO.



The microplate was then incubated in the dark at room temperature overnight. Absorbance of each well was then measured using a microplate reader. The selectivity index (SI) was determined by dividing the IC₅₀ value for normal Vero cells by the IC₅₀ value for MCF-7 cancer cells. The SI is a parameter used to measure the safety of a drug, calculated using equation [1].

$$SI = \frac{IC_{50} \text{ normal cells}}{IC_{50} \text{ cancer cells}} \quad [1]$$

A SI greater than 2 indicated that a sample exhibits cytotoxic activity against cancer cells without affecting normal cells (Rashidi et al., 2017).

Statistical analysis

The *in vitro* test presents the cytotoxic activity test data as absorbance values. These values are then used to calculate the percentage of viable cells (% cell viability) and to determine the statistical significance as well as the 50% inhibitory concentration (IC₅₀) values for the compounds bis-2-chlorobenzyl-oxychalcone, bis-3-chlorobenzyl-oxychalcone, and the reference compound tamoxifen, through probit analysis using SPSS version 27. The cell viability percentage (% cell viability) is calculated using the following equation [2].

$$\text{Cell viability (\%)} = \frac{(At . Ab)}{(Ac . Ab)} \times 100 \quad [2]$$

Where At: Absorbance of test; Ab: Absorbance of blank (media); and Ac: Absorbance of control (cells).

RESULTS AND DISCUSSION

Docking validation score

After performing the validation method by redocking the native ligand on the protein, whose native ligand was removed, the RMSD value was obtained: 2.42 Å. The tolerable RMSD value was ≤3.0 Å (Ramírez and Caballero, 2018).

In silico molecular docking

The molecular docking results for the reference compound tamoxifen, along with the test compounds bis-2-chlorobenzyl-oxychalcone and bis-3-chlorobenzyl-oxychalcone, using the Autodock 4.2.6 program, are summarized in Table 1. The interactions between the ligand molecules and receptors, as presented in Table 1, show that bis-2-chlorobenzyl-oxychalcone and bis-3-chlorobenzyl-oxychalcone demonstrated docking scores of -11.54 kcal/mol and

-11.92 kcal/mol, respectively, which are lower than those of tamoxifen (-10.00 kcal/mol) and pinostrobin (-10.07 kcal/mol). This lower binding energy suggests that the interactions between bis-2-chlorobenzyl-oxychalcone and bis-3-chlorobenzyl-oxychalcone with their receptors are more stable, as less energy is required for binding (Amelia et al., 2024). The binding energy values and interactions between ligands and amino acids are detailed in Table 1. The binding energy of chalcone compounds and their derivatives can be used to predict their biological activity, with lower binding energy indicating stronger ligand-receptor interactions and greater potential activity. The more hydrogen bonds and steric interactions (Van der Waals and hydrophobic interactions) formed between the ligand and receptor, the more stable the ligand-receptor complex is expected to be bis-2-chlorobenzyl-oxychalcone interacts with the ER-α receptor through steric interactions (Van der Waals and hydrophobic interactions) with the amino acids Arg 394, Glu 353, Gly 521, Leu 349, Leu 428, Phe 404, Thr 347, Asp 351, Met 421, Leu 525, Met 388, Met 343, Leu 346, Trp 383, Ala 350, Leu 354, Leu 384, Leu 387, and Leu 391. Similarly, bis-3-chlorobenzyl-oxychalcone interacts with amino acids Arg 394, Asp 351, Gly 521, Leu 354, Leu 428, Leu 384, Met 343, Phe 404, Thr 347, Glu 353, Leu 346, His 524, Ala 350, Ile 424, Leu 349, Leu 387, Leu 391, Leu 525, Met 388, and Met 421. In comparison, tamoxifen interacts with the ER-α receptor through hydrogen bonds with the amino acid Thr 347 and steric interactions with amino acids Arg 394, Asp 351, Glu 353, Gly 521, His 524, Ile 424, Leu 354, Leu 384, Leu 391, Met 343, Met 421, Trp 383, and Thr 347. Therefore, it can be concluded that chalcone and its derivatives can interact with the ER-α receptor due to their ability to form bonds with the same residues amino acids as tamoxifen, including Arg 394, Asp 351, Glu 353, Gly 521, His 524, Leu 349, Leu 354, Leu 384, Met 343, Phe 404, Trp 383, Thr 347, Ala 350, Leu 346, Leu 387, Leu 391, Ile 424, Leu 428, Leu 525, Met 388, and Met 421.

Isolation of compounds

From powdered *B. rotunda* simplicia (2 kg), 10.50 grams of pinostrobin crystals were isolated, yielding white crystals with a yield of 0.525% and a melting point of 99.5°C-101.4°C. The IR spectrum showed ν_{max} (cm⁻¹): 3058 (–OH phenolic); 2972-2912 (=C–H aromatic); 1638-1526 (C=C aromatic); 1284-1034 (C–O ether); and 887-698 (C–H aromatic). ¹H-NMR (chloroform-D, 400 MHz). δ 2.82 (d, J=2 Hz, 1H); δ 3.09 (d, J=12 Hz, 1H); δ 3.80 (s, 3H); δ 5.42 (d, J=4 Hz, 1H); δ 6.06 (m, 2H); δ 7.41 (m, 5H); δ 12.02 (s, 1H). The IR and ¹H-NMR spectrum can be seen in Fig. 2A-B.

Synthesis of chalcone compounds

The synthesis procedure was based on a modified green synthesis method using the Williamson ether reaction, with microwave irradiation and a phase-transfer catalyst (PTC). Chalcone compounds were synthesized from pinostrobin, which was isolated from *B. rotunda*. Chalcones have been shown to exhibit

it strong biological activity and potential as chemotherapeutic agents, but their natural occurrence is limited compared to other flavonoid compounds. Therefore, an efficient synthetic method is needed, following the principles of Green Chemistry. The synthesis involved reacting pinostrobin with 2-chlorobenzyl chloride and pinostrobin with 3-chlorobenzyl chloride.

Table 1. Binding energy and interaction binding between chalcone derivatives and receptors.






Ligand	Binding energy (kcal/mol)	Interaction binding	Amino acid residues
Pinostrobin	-10.07		Arg 394; Glu 353; Gly 420; Gly 521; Leu 349; Met 388; Thr 347; Met 421; His 524; Phe 404; Ala 350; Ile 424; Leu 387; Leu 346; Leu 525; Leu 391; Met 343; Trp 383
Chalcone	-11.35		Arg 394; Asp 351; Gly 420; Gly 521; Leu 384; Phe 404; Thr 347; His 534; Glu 353; Met 343; Trp 383; Leu 525; Ala 350; Ile 424; Leu 387; Leu 346; Leu 349; Leu 391; Leu 428; Met 388; Met 421
Bis-2-chlorobenzyloxychalcone	-11.54		Arg 394; Glu 353; Gly 521; Leu 349; Leu 428; Phe 404; Thr 347; Asp 351; Met 421; Leu 525; Met 388; Met 343; Leu 346; Trp 383; Ala 350; Leu 354; Leu 536; Leu 384; Leu 387; Leu 391; Met 528

Table 1. Binding energy and interaction binding between chalcone derivatives and receptors (continued...)

Ligand	Binding energy (kcal/mol)	Interaction binding	Amino acid residues
Bis-3-chlorobenzoyloxychalcone	-11.92		Arg 394; Asp 351; Gly 420; Gly 521; Leu 354; Leu 428; Leu 384; Met 343; Phe 404; Thr 347; Glu 353; Leu 346; His 524; Ala 350; Ile 424; Leu 349; Leu 387; Leu 391; Leu 349; Leu 525; Met 388; Met 421; Trp 383
Tamoxifen	-10.00		Arg 394; Asp 351; Glu 491; Gly 420; Gly 521; His 524; Leu 349; Leu 354; Leu 384; Met 343; Phe 404; Trp 383; Thr 347; Ala 350; Leu 346; Leu 387; Leu 391; Ile 424; Leu 428; Leu 525; Met 388; Met 421

Bis-2-chlorobenzoyloxychalcone

Melting points 99.6-101.6°C. The IR spectrum showed, ν_{max} (cm⁻¹): 2920-2849 (=C-H aromatic); 1675-1602 (C=C aromatic); 1293-1034 (C-O ether). ¹H-NMR (chloroform-D, 400 MHz). δ 3.77 (s, 2H); δ 3.77 (m, 1H); δ 3.93 (m, 1); δ 4.075 (s, 1H); δ 4.813 (s, 1H); δ 5.15 (m, 1H); δ 5.23 (s, 1H); δ 6.08 (m, 1H); δ 6.45 (s, 1H); δ 6.82 (m, 6H); δ 7.27 (m, 7H); and δ 7.77 (m, 1H), The IR and ¹H-NMR spectrum can be seen in Fig. 2 C-D.

Bis-3-chlorobenzoyloxychalcone

Melting points 99.3-101.2°C. IR, ν_{max} (cm⁻¹): 2920-2853 (=C-H aromatic); 1623 (C=C aromatic); 1298-1034 (C-O eter). ¹H-NMR (chloroform-D, 400 MHz). δ 3.77 (s, 3H); δ 5.03 (s, 4H); δ 6.16 (s, 1H); δ 7.01 (d, 1H); δ 7.18 (m, 7H); δ 7.30 (m, 2H); δ 7.37 (m, 4H); and δ 7.50 (m, 2H), The IR and ¹H-NMR spectrum can be seen in Fig. 2E-F.

In vitro tests

The summary of IC₅₀ values for the test compounds and control against MCF-7 cancer cells and normal Vero cells can be seen in Table 2. The table shows that the IC₅₀ values for the test compounds bis-2-chlorobenzoyloxychalcone and bis-3-chlorobenzoyloxychalcone against MCF-7 cells were 251.175 $\mu\text{g/mL}$ (0.484 mM) and 81.050 $\mu\text{g/mL}$ (0.156 mM), respectively, while the reference compound tamoxifen showed an IC₅₀ of 1,46 $\mu\text{g/mL}$ (0.002 mM). According to the National Cancer Institute (2021) guidelines, a compound is classified as highly cytotoxic if it exhibits an IC₅₀ value below 30 $\mu\text{g/mL}$. A compound is considered moderately cytotoxic when its IC₅₀ value falls between 30 $\mu\text{g/mL}$ and 100 $\mu\text{g/mL}$. In contrast, a compound is regarded as inactive if its IC₅₀ value exceeds 100 $\mu\text{g/mL}$. Based on these results, it was concluded that bis-2-chlorobenzoyloxychalcone demonstrates no significant cytotoxic activity, whereas bis-3-chlorobenzoyloxychalcone exhibits moderate cytotoxic effects. In contrast, tamoxifen displayed potent cytotoxic activity against MCF-7 cells.




Figure 2. The structure and spectra of pinostroin, bis-2-chlorobenzyloxchalcone, and bis-3-chlorobenzyloxchalcone. (A) IR spectrum of pinostroin. (B) ¹H- NMR spectrum of pinostroin (400 MHz). (C) IR spectrum of bis-2-chlorobenzyloxchalcone. (D) ¹H- NMR spectrum (400 MHz) of bis-2-chlorobenzyloxchalcone. (E) IR spectrum of bis-3-chlorobenzyloxchalcone. (F) ¹H- NMR spectrum (400 MHz) of bis-3-chlorobenzyloxchalcone.

Table 2. Summary of IC₅₀ values of the test and reference compounds against MCF-7 cancer cells and normal Vero cells.

Compound	IC ₅₀ MCF-7 cancer cell		IC ₅₀ Vero cell		Selectivity index (SI)
	(µg/mL)	(mM)	(µg/mL)	(mM)	
Bis-2-chlorobenzyloxchalcone	251.175	0.484	1068.36	2.057	4.253
Bis-3-chlorobenzyloxchalcone	81.040	0.156	304.32	0.586	3.755
Tamoxifen	1.460	0.002	1.472	-	1.008

For normal Vero cells, the IC₅₀ values of bis-2-chlorobenzoyloxychalcone and bis-3-chlorobenzoyloxychalcone were 1068.36 µg/mL (2.057 mM) and 304.32 µg/mL (0.586 mM), respectively, while tamoxifen had an IC₅₀ value of 1.472 µg/mL. From these results, it was concluded that both bis-2-chlorobenzoyloxychalcone and bis-3-chlorobenzoyloxychalcone have no cytotoxic effect on normal Vero cells, whereas tamoxifen is highly cytotoxic to normal cells.

Neither bis-2-chlorobenzoyloxychalcone nor bis-3-chlorobenzoyloxychalcone is more potent against MCF-7 cancer cells compared to the reference compound, tamoxifen. As the concentration increases, tamoxifen becomes more potent, while bis-2-chlorobenzoyloxychalcone and bis-3-chlorobenzoyloxychalcone require much higher concentrations to achieve comparable potency in killing MCF-7 cancer cells.

The IC₅₀ value of bis-2-chlorobenzoyloxychalcone indicates inactive cytotoxic activity as its value exceeds the required threshold and is significantly higher than that of bis-3-chlorobenzoyloxychalcone. This may be due to the steric hindrance at the ortho position of the benzene ring. In contrast, bis-3-chlorobenzoyloxychalcone has its substituent at the meta position on the benzene ring. This observation is supported by previous studies conducted by Karki et al. (2010) and Guo et al. (2021), which state that compounds with substituents in the ortho position tend to exhibit weaker activity compared to those with substituents in the meta or para positions. The position of substituents on the benzene ring can significantly influence a compound's biological activity, including its cytotoxicity. The terms ortho, meta, and para refer to the relative positions of substituents on an aromatic ring. If the substituent is in the ortho position (adjacent to each other on the ring), steric hindrance can occur, leading to unfavorable interactions and reduced cytotoxic activity. In the meta position (separated by one carbon on the ring), the steric and electronic properties may enhance interactions, thereby improving cytotoxicity. Meanwhile, in the para position (opposite on the ring), interactions with the biological target are often more optimal due to reduced steric hindrance and more favorable electronic effects.

Based on the SI data, tamoxifen has an SI value of 1.008, while bis-2-chlorobenzoyloxychalcone and bis-3-chlorobenzoyloxychalcone have SI values of 4.25 and 3.76, respectively. These results suggest that both compounds have SI values above 2, which indicates greater selectivity in targeting MCF-7 cancer cells over normal Vero cells. In other words, the synthesized compounds (bis-2-chlorobenzoyloxychalcone and bis-3-chlorobenzoyloxychalcone) could be potential alternatives for breast cancer therapy. However, in

terms of their activity against MCF-7 cancer cells, bis-2-chlorobenzoyloxychalcone is categorized as not very active, while bis-3-chlorobenzoyloxychalcone is considered moderately active. Despite this, both compounds can still be viable options due to their favorable SI values, which could help reduce the side effects typically associated with cancer treatments.

CONCLUSION

The compound bis-2-chlorobenzoyloxychalcone has an IC₅₀ value greater than 100 µg/mL, indicating that it exhibits inactive activity. In contrast, bis-3-chlorobenzoyloxychalcone has an IC₅₀ value of less than 100 µg/mL, suggesting that it possesses moderately active cytotoxic activity. The reference compound, tamoxifen, shows highly active cytotoxicity against MCF-7 cells. Chalcone derivatives require higher concentrations to increase their potency in killing MCF-7 breast cancer cells. However, they exhibit selectivity in targeting these cancer cells. The compounds bis-2-chlorobenzoyloxychalcone and bis-3-chlorobenzoyloxychalcone demonstrate cytotoxic activity against breast cancer cells, making them candidates for anticancer medications.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

ACKNOWLEDGMENTS

This study received financial assistance from Direktorat Riset, Teknologi, dan Pengabdian Kepada Masyarakat (DRTPM) Kementerian Pendidikan, Kebudayaan, Riset, dan Teknologi (KemendikbudRistek) through the funding scheme for Penelitian Tesis Magister Tahun Anggaran 2024 (Letter: 038/SP-Lit/LPPM-01/KemendikbudRistek/FF/VI/2024).

REFERENCES

- Ali S, Rasool M, Chaoudhry H, Pushparaj PN, Jha P, Hafiz A, Mahfooz M, Sami GA, Kamal MA, Bashir S, Ali A, Jamal MS (2016) Molecular mechanisms and mode of tamoxifen resistance in breast cancer. *Bioinformation* 12(3): 135–139. <https://doi.org/10.6026/97320630012135>
- Amelia MA, Kesuma D, Kirtishanti A, Sumartha IGA, Claudya M (2024) Molecular docking: study of chalcone derivatives from *Boesenbergia pandurata* targeting estrogen receptor alpha (ER-α) for breast cancer. *J Penelit Pendidik* 10(11): 8376–8386. <https://doi.org/10.29303/jppipa.v10i11.8734>
- Atun S, Handayani S (2017) *Phytochemistry of Temu Kunci Plant (Boesenbergia rotunda): Isolation, Structural Identification, Biological Activity, and Synthesis of Its Nanoparticle Products*. [Indonesian]. Yogyakarta, Indonesia: K-Media.
- Backer CA, Bakhuizen Van Den Brink RC (1968) *Flora of Java (Spermatophytes Only)* (vol. 3). Groningen: NVP Noordhoff.
- Clusan L, Ferrière F, Flouriot G, Pakdel F (2023) A basic review on estrogen receptor signaling pathways in breast cancer. *Int J Mol Sci* 24(7): 6834. <https://doi.org/10.3390/ijms24076834>

Dona R, Frimayanti N, Ikhtiarudin I, Iskandar B, Maulana F, Silalahi NT (2019) *In silico*, synthesis and cytotoxic activity of p-methoxy chalcone on human breast cancer MCF-7 cell line. *J Sains Farm Klin* 6(3): 243–249. <https://doi.org/10.25077/jsfk.6.3.243-249.2019>

Goldman B (2003) Multidrug resistance: Can new drugs help chemotherapy score against cancer? *J Natl Cancer Inst* 95(4): 255–257. <https://doi.org/10.1093/jnci/95.4.255>

Guo HY, Chen ZA, Shen QK, Quan ZS (2021) Application of triazoles in the structural modification of natural products. *J Enzyme Inhib Med Chem* 36(1): 1115–1144. <https://doi.org/10.1080/14756366.2021.1890066>

Kar A (2007) *Medicinal Chemistry* (4th ed.). New Delhi: New Age International Ltd Publisher.

Karki R, Thapa P, Kang MJ, Jeong TC, Nam JM, Kim HL, Na Y, Cho WJ, Kwon Y, Lee E (2010) Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure–activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines. *Bioorg Med Chem* 18(9): 3066–3077. <https://doi.org/10.1016/j.bmc.2010.03.051>

Kesuma D, Siswandono, Kirtishanti A (2022) Molecular docking and biological activity of n- (4-methoxy)-benzoyl-n'-phenylthiourea and n-(4 4-trifluoro)-benzoyl-n'-phenylthiourea as antibreast cancer candidates. *RASAYAN J Chem* 15(2): 1503–1508. <https://doi.org/10.31788/RJC.2022.1526836>

Kesuma D, Yuniarta TA, Suherto AD, Putra GS, Sutrisno S, Anwari F (2025) Synthesis, molecular docking, molecular dynamics, pharmacokinetics prediction and bioassay of N-(phenylcarbamothioyl)-4-chlorobenzamide as anti-breast cancer candidate. *J Pharm Pharmacogn Res* 13(2): 551–564. https://doi.org/10.56499/jppres24.2092_13.2.551

McMurry J (2011) *Fundamentals of Organic Chemistry* (7th ed.). Brooks/Cole Cengage Learning.

Moerkens M, Zhang Y, Wester L, van de Water B, Meerman JH (2014) Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation. *BMC Cancer* 14(1): 283. <https://doi.org/10.1186/1471-2407-14-283>

National Cancer Institute (2021) *Cancer*. National Cancer Institute. <https://www.cancer.gov/about-cancer/understanding/what-is-cancer> [Consulted 18 January, 2023].

Ogba N, Manning NG, Bliesner BS, Ambler SK, Haughian JM, Pinto MP, Jedlicka P, Joensuu K, Heikkilä P, Horwitz KB (2014) Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. *Breast Cancer Res* 16(6): 489. <https://doi.org/10.1186/s13058-014-0489-4>

Pavia LD, Lampman GM, Kriz GN (2009) *Introduction to spectroscopy* (3rd ed.). Thomson Learning, Inc.

Pratama MRF, Praditapuspa EN, Kesuma D, Poerwono H, Widiandani T, Siswodihardjo S (2022) *Boesenbergia pandurata* as an anti-breast cancer agent: Molecular docking and ADMET study. *Lett Drug Des Discov* 19(7): 606–626. <https://doi.org/10.2174/1570180819666211220111245>

Ramírez D, Caballero J (2018) Is it reliable to take the molecular docking top scoring position as the best solution without considering available structural data? *Molecules* 23(5): 1038. <https://doi.org/10.3390/molecules23051038>

Rashidi M, Seghatoleslam A, Namavari M, Amiri A, Fahmidehkar MA, Ramezan A, Eftekhari E, Hosseini A, Erfani N, Fakher S (2017) Selective cytotoxicity and apoptosis-induction of *Cyrtopodion scabrum* extract against digestive cancer cell lines. *Int J Cancer Manag* 10(5): e8633. <https://doi.org/10.5812/ijcm.8633>

Siswandono (2016) *Kimia Medisinal 1* (Edisi Kedua). Airlangga University Press.

Sun X, Zhao P, Lin J, Chen K, Shen J (2023) Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system. *Cancer Drug Resist* 6(2): 390–415. <https://doi.org/10.20517/cdr.2023.16>

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 71(3): 209–249. <https://doi.org/10.3322/caac.21660>

Tartarone A, Lazzari C, Leroze R, Conteduca V, Improta G, Zupa A, Bulotta A, Aieta M, Gregorc V (2013) Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. *Lung Cancer* 81(3): 328–336. <https://doi.org/10.1016/j.lungcan.2013.05.020>

The Global Cancer Observatory (2021) *Globocan 2020: Indonesia*. <https://gco.iarc.who.int/media/globocan/factsheets/populations/360-indonesia-fact-sheet.pdf> [Consulted 18 January, 2023].

Van Steenis C (2008) *FLORA: untuk Sekolah di Indonesia*. Jakarta: Pradnya Paramita.

Villa SM, Heckman J, Bandyopadhyay D (2024) Medicinally privileged natural chalcones: abundance, mechanisms of action, and clinical trials. *Int J Mol Sci* 25(17): 9623. <https://doi.org/10.3390/ijms25179623>

AUTHOR CONTRIBUTION:

Contribution	Amelia MA	Kesuma D	Kirtishanti A	Sumartha IGA	Claudia M
Concepts or ideas	x	x	x	x	x
Design		x			
Definition of intellectual content	x	x	x	x	x
Literature search	x	x	x	x	x
Experimental studies	x			x	x
Data acquisition		x	x	x	
Data analysis		x	x	x	
Statistical analysis		x	x		
Manuscript preparation	x	x	x		
Manuscript editing	x	x	x		
Manuscript review	x	x	x	x	x

Citation Format: Amelia MA, Kesuma D, Kirtishanti A, Sumartha IGA, Claudya M (2025) Molecular docking, synthesis, and *in vitro* activity testing of chalcone derivatives from *Boesenbergia rotunda* (L.) Mansf. against MCF-7 breast cancer cells. J Pharm Pharmacogn Res 13(s1): S129–S139.
https://doi.org/10.56499/jppres24.2220_13.s1.129

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Open Access: This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.



JPPRes

**Journal of Pharmacy
& Pharmacognosy
Research**



We are a platform for pharmacy experts to share high-quality research on drug discovery, pharmacology and related topics.



Featured Articles

Pharmacists' patient care competency

October 18, 2020

[Read More](#)

Dear colleague,

You are cordially invited to submit a manuscript to the **Journal of Pharmacy & Pharmacognosy Research (JPPRes)** (ISSN 0719-4250), an international, bimonthly specialized and peer-reviewed open access journal devoted to the publication of original contributions in relevant areas, which publishes original research articles, reviews, letters and guest edited single topic issues in all areas of Pharmacy and Pharmacognosy in English or Spanish.

Papers of JPPRes are opening accessible at the journal's homepage: jppres.com, and

you are invited to read or download them freely for the academic exchanges.

The Audience of JPPRes could be: Biochemists, Biotechnologists, Botanists, Chemical Engineers, Clinical Pharmacologists, Medical Scientists, Medicinal Chemists, Natural Product Chemists, Pharmaceutical Scientists, Pharmacologists, Pathologists, Plant Scientists, and Toxicologists, among others.

Frequency of publication: Electronic versions of articles are published immediately and continuously once the manuscripts have been accepted. JPPRes has an acceptance rate of 33.6% (2022). The average time between submission and final decision is 100 days and the average time between acceptance and final publication is 15 days. JPPRes does not charge any fee for authors submitting manuscripts. However, an article-processing charge **(APC) of 600 USD (US Dollars)** applies to papers accepted after peer review.

You are welcome to submit your manuscript to this journal through the following link: [submit article](#)

Please, visit the [Author Guidelines](#), [Submit an Article](#) or [contact us](#) if you have any questions about the journal.

Best regards,

Prof. Gabino Garrido

Editor in Chief

[E-mail](#)

Indexed In:

Clarivate Master Journal List
JIF (2024): 1.0
2024 Journal Citation Reports™ (Clarivate, 2025)

CiteScore: 3.2 (2024)
(Scopus, 2025)

Google Scholar



Latest Articles

Antibacterial plants from Gayo Lues Highland

January 9, 2023

[Read More](#)**Targeted proteins for vaginal epithelial repair**

January 2, 2023

[Read More](#)**Bioadsorption of silver ions by chitin derivatives**

January 2, 2023

[Read More](#)[1](#) [2](#) [3](#) [...](#) [67](#)

Current Issue:



Volume 13, Issue 4



Volume 13, supplement 1

Recently Published Issues by Year:

2025

2024

2023

2022

2021

2019

2018

2017

2016

2015

2014

2013

Issue In Progress:



Volume 13, Issue 5

Last Update: July 16th, 2025



JPPRes

**Journal of Pharmacy
& Pharmacognosy
Research**

[Home](#) [About](#) [Archive](#) [Authors](#) [Reviewers](#) [Events](#) [Blog](#)

[!\[\]\(e2906a780c2bbcdc2a236d79598e58f1_img.jpg\) Twitter](#) [!\[\]\(b46c7f04a8d398c60eb357f7415c967f_img.jpg\) LinkedIn](#) [!\[\]\(33ab5a78aa84cc698a8e599bbdc3ba81_img.jpg\) Facebook](#)

© 2013–2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license–Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by **AVAGAX Studio**



JPPRes

Journal of Pharmacy
& Pharmacognosy
Research



Editorial Board



JPPRes

Journal of Pharmacy
& Pharmacognosy
Research

Gabino Garrido

Editor-in-Chief

[Scholar Google](#)

[Scopus](#)

[ResearchGate](#)

[ORCHID](#)

GarVal Editorial Ltda.

[Email](#)

Marisela Valdés González

Executive Editor

ORCID

GarVal Editorial Ltda.

Email

Xavier Garrido

Editorial and Design Manager

LinkedIn

Behance

Web

AVAGAX Studio

Antofagasta, Chile

Email

Editorial Board Members

**Antonio Vassallo**

Dipartimento di Scienze. Università degli Studi della Basilicata, Potenza, Italia.

[Research Gate](#)[ORCID](#)[Scopus](#)**Bárbara B. Garrido Suárez**

Laboratorio de Farmacología y Toxicología, Centro de Investigación y Desarrollo de Medicamentos, La Habana, Cuba.

[Research Gate](#)[ORCID](#)**Carla Delporte**

Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile

[Research Gate](#)[ORCID](#)**Damaris Silveira**

Faculdade de Ciências da Saúde, Universidade de Brasília, Brazil

[Lattes](#)

[ORCID](#)



Douglas S. de Almeida Chaves

Dep. de Ciências Farmacêuticas (DCFar), Instituto de Ciências Biológicas e da Saúde,
Universidade Federal Rural do Rio de Janeiro, Rodovia, RJ. Brazil

[ResearchGate](#)

[ORCID](#)

[Lattes](#)



Edgar Pastene

Universidad de Concepción, Concepción, Chile

[ResearchGate](#)

[ORCID](#)



Etile Spegazzini

Universidad de Belgrano, Buenos Aires, Argentina

[ResearchGate](#)



Farid Chemat

Université Avignon et des Pays de Vaucluse, Avignon, France

[ResearchGate](#)



Fidel O. Castro

Departamento de Ciencias Pecuarias, Universidad de Concepción, Chillán, Chile

[ResearchGate](#)

[ORCID](#)



Guilherme N. L. do Nascimento

Universidade Federal de Tocantins. Brazil

[ORCID](#)



Jacqueline Sepúlveda

Universidad de Concepción, Concepción, Chile

[ResearchGate](#)

[ORCID](#)



Jelena Nadinic

Universidad de Buenos Aires, Argentina.

ResearchGate

ORCID



José H. Isaza-Martínez

Universidad del Valle, Cali, Colombia

ResearchGate

ORCID



Juan C. Sepúlveda-Arias

Universidad Tecnológica de Pereira, Pereira, Colombia

ResearchGate

ORCID



Madan Mohan Gupta

School of Pharmacy, Faculty of Medical Sciences. The University of the West Indies,
Trinidad & Tobago, West Indies

Google Scholar

ORCID

**Mahomoodally M. Fawzi**

Department of Health Sciences, Faculty of Science, University of Mauritius. Mauritius.

[ORCID](#)[ResearchGate](#)**María Inés Isla**

Facultad de Ciencias Naturales e Instituto Miguel Lillo. Universidad Nacional de Tucumán, Tucumán, Argentina.

[ResearchGate](#)[ORCID](#)**Marisol Fernández Alfonso**

Facultad de Farmacia, Universidad Complutense de Madrid, España

[ResearchGate](#)[ORCID](#)**Mayank Gangwar**

Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi (UP) India

[Scholar Google](#)[ORCID](#)**Silvia Debenedetti**

Pharmacy Carreer. Universidad de Belgrano, Buenos Aires, Argentina

[ORCID](#)[ResearchGate](#)**Vikash Kumar Ruhil**

PDM College of Pharmacy, Bahadurgarh, Haryana, India

[Google Scholar](#)**Yasser Shahzad**

Department of Pharmacy. COMSATS University Islamabad, Pakistan

[Scopus](#)[ORCID](#)[Google Scholar](#)

Reviewers

The reviewers will be recruited among researchers and clinicians with high international reputation in Pharmacy and Pharmacognosy.

Last Update: August 20th, 2023



[Home](#) [About](#) [Archive](#) [Authors](#) [Reviewers](#) [Events](#) [Blog](#)

[!\[\]\(2de14ecdac8f3bd4221dec5cc1fcc44b_img.jpg\) Twitter](#) [!\[\]\(bb99c6067af6fc9851d75f8e704114f1_img.jpg\) LinkedIn](#) [!\[\]\(1fee1684805c31f41805c0ef87f53d12_img.jpg\) Facebook](#)

© 2013–2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license–Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by **AVAGAX Studio**

**JPPRes****Journal of Pharmacy
& Pharmacognosy
Research**

Volume 13, supplement 1

J Pharm Pharmacogn Res 13(Supplement 1), (April) 2025 (In Progress)

Special Issue

Bioinformatics and Phytobioinformatics: Advancing *In Silico* Approaches to Revolutionize Modern Healthcare. Part 1.



IFC (Journal of Pharmacy & Pharmacognosy Research).

1.- Original Article

Ria Nur Puspa Sari, Fadilah (2025) **Machine learning-approaches insights into metabolomics for type 2 diabetes mellitus.** [Perspectivas metabolómicas para la diabetes mellitus tipo 2 basadas en aprendizaje automático]. J Pharm Pharmacogn Res 13(suppl. 1): S1–S12. https://doi.org/10.56499/jppres24.2108_13.s1.1  [767 Kb]
[ABSTRACT]

2.- Original Article

Henny Kasmawati, Ruslin Ruslin, Arfan Arfan, Nurramadhani A.Sida, Agustono Wibowo, Megat Ahmad Kamal Megat Hanafiah, Mohd Fazli Mohammad Yahya (2025) **In-depth insights into the antidiabetic activity of *Dracaena trifasciata* (Prain) Mabb. fractions**

and subfractions: *In vitro* and computational studies. [Análisis en profundidad de la actividad antidiabética de fracciones y subfracciones de *Dracaena trifasciata* (Prain) Mabb.: Estudios *in vitro* y computacionales]. J Pharm Pharmacogn Res 13(suppl. 1): S13–S26. https://doi.org/10.56499/jppres24.2193_13.s1.13  [1.02 Mb] [ABSTRACT]

3.– Original Article

Gugulethu M. Miya, Ayodeji O. Oriola, Pallab Kar, Adebola O. Oyedeji (2025) **Isolation and characterization of fatty acid esters from *Cyperus marginatus* Thunb. leaf, their *in vitro* biological and *in silico* molecular docking studies.** [Aislamiento y caracterización de ésteres de ácidos grasos de hojas de *Cyperus marginatus* Thunb., estudios de acoplamiento molecular *in silico* y biológico *in vitro*]. J Pharm Pharmacogn Res 13(suppl. 1): S27–S46. https://doi.org/10.56499/jppres24.2109_13.s1.27  [1.62 Mb] [ABSTRACT]

4.– Original Article

Aiko Zavira Permana, Naura Luviezka Choirunnisa, Debora Chris Kezia, Edwin Widodo, Happy Kurnia Permatasari, Hikmawan Wahyu Sulistomo, Eviana Nurahmawati, Nik Ahmad N. Nik Malek, Agustina Tri Endharti, Sofy Permana (2025) ***In silico* prediction of MMP-2 pathway related to anticancer effects of *Sterculia foetida* L.** [Predicción *in silico* de la vía MMP-2 relacionada con los efectos anticancerígenos de *Sterculia foetida* L.]. J Pharm Pharmacogn Res 13(suppl. 1): S47–S57. https://doi.org/10.56499/jppres24.2110_13.s1.47  [566 Kb] [ABSTRACT]

5.– Original Article

Ahmad Najib, Rahmawati, Rezki Amriati Syarif, Hasnaeni, Andi Ummu Aiman, Andi Sakti (2025) **Exploration of antitumor compounds in *Syzygium oblanceolatum* (C.B.Rob.) Merr. stem bark using *in silico* method.** [Exploración de compuestos antitumorales en corteza del tallo de *Syzygium oblanceolatum* (C.B.Rob.) Merr. utilizando el método *in silico*]. J Pharm Pharmacogn Res 13(suppl. 1): S58–S66. https://doi.org/10.56499/jppres24.2222_13.s1.58  [566 Kb] [ABSTRACT]

6.– Original Article

Silvi Zakiyatul Ilmiyah, Sofy Permana, Edwin Widodo, Eviana Norahmawati, Happy Kurnia Permatasari, Yoshiyuki Kawamoto, Nik Ahmad Nizam Nik Malek, Agustina Tri Endharti (2025) **Exploring anti-cancer potential of *Anredera cordifolia* (Ten.) Steenis leaf compounds against MMP-2 receptor in breast cancer: An *in silico* approach.** [Exploración del potencial anticancerígeno de los compuestos de las hojas de *Anredera cordifolia* (Ten.) Steenis contra el receptor MMP-2 en el cáncer de mama: Un enfoque *in silico*]. J Pharm Pharmacogn Res 13(suppl. 1): S67–S82. https://doi.org/10.56499/jppres24.2129_13.s1.s67  [1.59 Mb] [ABSTRACT]

7.- Original Article

Ruswanto Ruswanto, Tita Nofianti, Indra Indra, Richa Mardianingrum, Sofa Fajriah, Aska Reisya Aulia, Zahra Putri Handirana, Sheilla Fitriani Zahwa (2025) **Modification of 5-fluorouracil with thiourea and benzoyl groups and *in silico* study on thymidylate synthase enzyme as an anticancer candidate.** [Modificación del 5-fluorouracilo con grupos tiourea y benzoilo y estudio *in silico* de la enzima timidilato sintasa como candidato anticancerígeno]. J Pharm Pharmacogn Res 13(suppl. 1): S83–S99. https://doi.org/10.56499/jppres24.2216_13.s1.83  [1.72 Mb] [ABSTRACT]

8.- Original Article

Faris Izzatur Rahman, Anissa Nofita Sari, Khalish Arsy Al Khairy Siregar, Indira Prakoso, Aigia Syahraini, Eka Gunarti Ningsih, Essy Harnelly, Zulkarnain Zulkarnain (2025) **Revealing *Pogostemon cablin* (Blanco) Benth. and *Murraya koenigii* (L.) Spreng. action targets on AKT1 as papillary thyroid cancer therapy based on bioinformatics approach.** [Revelación de las dianas de acción de *Pogostemon cablin* (Blanco) Benth. y *Murraya koenigii* (L.) Spreng. sobre AKT1 como terapia del cáncer papilar de tiroides basada en un enfoque bioinformático]. J Pharm Pharmacogn Res 13(suppl. 1): S100–S117. https://doi.org/10.56499/jppres24.2163_13.s1.100  [1.48 Mb] [ABSTRACT]

9.- Original Article

Ruri Y. Astari, Sri Winarsih, Dian Handayani, Heni D. Windarwati, Holipah, Bambang Rahardjo (2025) ***In silico* analysis of *Ziziphus mauritiana* Lam. bioactive compounds targeting GABA receptor and ADMET profiles for potential postpartum depression treatment.** [Análisis *in silico* de compuestos bioactivos de *Ziziphus mauritiana* Lam. dirigidos al receptor GABA y perfiles ADMET para el posible tratamiento de la

depresión posparto]. J Pharm Pharmacogn Res 13(suppl. 1): S118–S128. https://doi.org/10.56499/jppres24.2239_13.s1.118  [511 Kb] [ABSTRACT]

10.– Original Article

Marsha A. Amelia, Dini Kesuma, Aguslina Kirtishanti, I Gede A. Sumartha, Maria Claudya (2025) **Molecular docking, synthesis, and *in vitro* activity testing of chalcone derivatives from *Boesenbergia rotunda* (L.) Mansf. against MCF-7 breast cancer cells.** [Acoplamiento molecular, síntesis y actividad *in vitro* de derivados de chalcona de *Boesenbergia rotunda* (L.) Mansf. contra células MCF-7 de cáncer de mama]. J Pharm Pharmacogn Res 13(suppl. 1): S129–S139. https://doi.org/10.56499/jppres24.2220_13.s1.129  [1.11 Mb] [ABSTRACT]

11.– Original Article

Sutrisno Sutrisno, Maharani Maharani (2025) **Network pharmacology and molecular docking of *Phaleria macrocarpa* (Scheff.) Boerl. bioactive compounds involved in endometriosis pathway.** [Farmacología en red y acoplamiento molecular de compuestos bioactivos de *Phaleria macrocarpa* (Scheff.) Boerl. implicados en la vía de la endometriosis]. J Pharm Pharmacogn Res 13(suppl. 1): S140–S152. https://doi.org/10.56499/jppres24.2238_13.s1.140  [1.10 Mb] [ABSTRACT]

© 2025 Journal of Pharmacy & Pharmacognosy Research (JPPRes)



JPPRes

Journal of Pharmacy
& Pharmacognosy
Research

[Home](#) [About](#) [Archive](#) [Authors](#) [Reviewers](#) [Events](#) [Blog](#)

[!\[\]\(986082884a323475ef59af56b5554821_img.jpg\) Twitter](#) [!\[\]\(4b04e3a9e2399d4e61f666959a05c66b_img.jpg\) LinkedIn](#) [!\[\]\(ef430d48c7249bd39ff9dc2ec15a483a_img.jpg\) Facebook](#)

© 2013–2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license–Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by **AVAGAX Studio**

SJR

Scimago Journal & Country Rank

Enter Journal Title, ISSN or Publisher Name

Home

Journal Rankings

Journal Value

Country Rankings

Viz Tools

Help

About Us

CrowdStrike®

Download

Journal of Pharmacy and Pharmacognosy Research

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	SJR 2024
Chile Universities and research institutions in Chile Media Ranking in Chile	Health Professions Pharmacy Medicine Complementary and Alternative Medicine Pharmacology, Toxicology and Pharmaceutics Drug Discovery Pharmaceutical Science Pharmacology	Asociacion Academica de Ciencias Farmaceuticas de Antofagasta (ASOCIFA)	0.314 q2 H-INDEX 21
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	07194250	2013-2025	Homepage How to publish in this journal editor@jppres.com

CrowdStrike®

2025 Global Threat Report

Download

SCOPE

The Journal of Pharmacy & Pharmacognosy Research (JPPRes) is an international, specialized and peer-reviewed open access journal, under the auspices of AVAGAX – Diseño, Publicidad y Servicios Informáticos, which publishes studies in the pharmaceutical and herbal fields concerned with the physical, botanical, chemical, biological, toxicological properties and clinical applications of molecular entities, active pharmaceutical ingredients, devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture, evaluation and marketing. This journal publishes research papers, reviews, commentaries and letters to the editor as well as special issues and review of pre-and post-graduate thesis from pharmacists or professionals involved in Pharmaceutical Sciences or Pharmacognosy.

Join the conversation about this journal

Ads by clickio

Close

2025 Global Threat Report

CrowdStrike®


Download

Quartiles

FIND SIMILAR JOURNALS


options

1 Advances in Pharmacological and Pharmaceutical Sciences GBR 70% similarity	2 Phytomedicine Plus NLD 70% similarity	3 Journal of Applied Pharmaceutical Science IND 67% similarity	4 Journal of Natural Remedies IND 67% similarity	5 Journal of HerbMed Pharmacology IRN 66% similarity
---	---	---	--	---



SCImago Graphica

Explore, visually communicate and make sense of data with our [new data visualization tool](#).



Metrics based on Scopus® data as of March 2025

Ads by



Gabino Garrido Garrido 4 years ago

Dear Melanie,
Thank you for your kind and quick reply.
Sincerely

reply



Gabino Garrido Garrido 4 years ago

Dear Scimagojr,
Please, some time ago I contacted Scimago in this way to see the possibility of incorporating my journal (Journal of Pharmacy and Pharmacognosy Research) into the Pharmacy category. I have not received any responses.
Hopefully, you can answer me if this is the appropriate way to make such a request.
Thank you!
Best regards.
Gabino Garrido,
editor-in-chief

reply



Melanie Ortiz 4 years ago

SCImago Team

Dear Gabino,
Thank you for contacting us.
SJR is a portal with scientometric indicators of journals indexed in Scopus. All the metadata (Title, ISSN, Publisher, Category, etc.) have been provided by Scopus /Elsevier and SCImago doesn't have the authority over these data which are property of Scopus/ Elsevier. SCImago is not allowed to do any changes of the metadata unless Scopus authorizes it expressly. SCImago has a signed agreement that limits our performance to the generation of scientometric indicators derived from the metadata sent in the last update. Keep also in mind that the SJR is a static image (the update is made only one time per year) of a database (Scopus) which is changing every day.
Therefore, we suggest you contact Scopus support regarding this matter here:
https://service.elsevier.com/app/answers/detail/a_id/14883/kw/scimago/supporthub/scopus/
Best Regards,
SCImago Team

Leave a comment

Name

Email

(will not be published)



I'm not a robot

reCAPTCHA
Privacy - Terms

Ads by

[Submit](#)

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2025. Data Source: Scopus®

EST MODUS IN REBUS
Hempes (Online 1.1.1991)

[Legal Notice](#)

[Privacy Policy](#)